Amphix Bio spun out from Northwestern University in Chicago, IL in 2021. The company is developing a new platform technology, Supramolecular Therapeutic Peptides (STPs), that modifies immunological response and initiates regenerative processes to restore function lost from injury, disease, or aging. These therapies trigger targeted signaling pathways while forming scaffolds to support biological repair. Amphix Bio's goal is to increase human healthspan - the length of time that people can live productive, fulfilling lives.
